STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARA
  4. [8-K] Protara Therapeutics, Inc. Reports Material Event

Protara Therapeutics (TARA) CMO Leonardo Nicacio resigns, duties reassigned

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Protara Therapeutics, Inc. reported that its Chief Medical Officer, Leonardo Viana Nicacio, M.D., has resigned from the company to explore other opportunities, effective June 26, 2026. His responsibilities will transition to Carla Beckham, M.D., the company’s Lead Medical Director and Head of Clinical Development, under the continued oversight of Jacqueline Zummo, Ph.D., Chief Research & Development Officer. This represents a leadership change in the company’s medical and clinical development organization.

Positive

  • None.

Negative

  • None.

Insights

Key R&D leadership change as CMO role is reallocated internally.

The resignation of Chief Medical Officer Leonardo Viana Nicacio, M.D. removes a senior leader from Protara’s clinical organization. CMO roles are central to shaping clinical strategy, regulatory interactions, and trial execution in development-stage biopharma companies.

The company states that his duties will be taken over by Lead Medical Director and Head of Clinical Development Carla Beckham, M.D., with oversight from Chief R&D Officer Jacqueline Zummo, Ph.D.. This suggests an internal redistribution of responsibilities rather than an immediate external replacement.

The eventual effectiveness of this transition will depend on how smoothly clinical and regulatory activities continue under the revised structure. Future disclosures in company filings may provide more detail on pipeline progress and any related organizational adjustments.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Chief Medical Officer financial
"Leonardo Viana Nicacio, M.D., Chief Medical Officer of the Company, resigned"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
Lead Medical Director financial
"will be subsumed by Carla Beckham, M.D., the Company's Lead Medical Director"
Head of Clinical Development financial
"Lead Medical Director and Head of Clinical Development, and will continue"
Chief Research & Development Officer financial
"under the oversight of Jacqueline Zummo, Ph.D., the Company's Chief Research & Development Officer"
Emerging growth company financial
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

What leadership change did Protara Therapeutics (TARA) disclose?
Protara Therapeutics disclosed that Chief Medical Officer Leonardo Viana Nicacio, M.D., resigned effective June 26, 2026. His departure affects senior oversight of clinical and medical functions within the company’s research and development organization.

When is the CMO resignation at Protara Therapeutics (TARA) effective?
The resignation of Chief Medical Officer Leonardo Viana Nicacio, M.D., is effective June 26, 2026. This is the date from which his responsibilities cease and internal leadership transitions take effect within the clinical organization.

Who will take over the Chief Medical Officer duties at Protara Therapeutics (TARA)?
Protara states that CMO duties will be handled by Carla Beckham, M.D., its Lead Medical Director and Head of Clinical Development. She will operate under the continued oversight of Chief Research & Development Officer Jacqueline Zummo, Ph.D..

Why did Protara Therapeutics’ CMO Leonardo Viana Nicacio resign?
The company reports that Chief Medical Officer Leonardo Viana Nicacio, M.D., resigned to “explore other opportunities.” No additional detail about his future plans or the circumstances of the decision is provided in the disclosure.

Does Protara Therapeutics (TARA) mention a replacement title for the CMO role?
Protara does not name a new Chief Medical Officer title. Instead, it reallocates the departing CMO’s responsibilities to Lead Medical Director and Head of Clinical Development Carla Beckham, M.D., overseen by Chief R&D Officer Jacqueline Zummo, Ph.D..

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001359931 0001359931 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 26, 2026

 

Protara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36694   20-4580525
(State or other jurisdiction
of incorporation) 		  (Commission File No.)   (IRS Employer
Identification No.)

 

345 Park Avenue South

Third Floor

New York, NY

   10010
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (646) 844-0337 

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TARA   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

  

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Protara Therapeutics, Inc. (the “Company”) announced that Leonardo Viana Nicacio, M.D., Chief Medical Officer of the Company, resigned from the Company to explore other opportunities, effective as of June 26, 2026. Dr. Nicacio's duties will be subsumed by Carla Beckham, M.D., the Company's Lead Medical Director and Head of Clinical Development, and will continue under the oversight of Jacqueline Zummo, Ph.D., the Company's Chief Research & Development Officer.

 

1 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 29, 2026

 

  Protara Therapeutics, Inc.
     
  By: /s/ Patrick Fabbio
    Patrick Fabbio
    Chief Financial Officer

 

2 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents